UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Key Inclusion Criteria * Newly diagnosed Age-related Macular Degeneration (AMD) * No previous treatment received for diagnosed AMD * Visual Acuity 6/7.5 to 6/96 Key Exclusion Criteria: * standard exclusion criteria for anti-VEGF treatment * Visual Acuity \<6/96 * nAMD in both eyes, or any condition in other eye which may have required anti- VEGF treatment during study period * other disease in candidate eye which could have compromised visual acuity or required medical/surgical intervention during study period * participation to other clinical study with 'not approved' treatment within a year prior to UNRAVEL study participation.